Skip to main content

Angiodynamics Value Stock - Dividend - Research Selection

Angiodynamics

ISIN: US03475V1017 , WKN: A0B9A5

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. In addition, the company provides thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. Further, it offers peripherally inserted central catheters; ports that are implantable devices for the central venous administration; and dialysis products. Additionally, the company provides microwave ablation products; radiofrequency ablation products for ablating solid cancerous or benign tumors; and NanoKnife ablation systems for the surgical ablation of soft tissues. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


AngioDynamics, Inc. (ANGO) Presents at UBS Global Healthcare Conference 2025 Transcript

2025-11-10
AngioDynamics, Inc. (ANGO) UBS Global Healthcare Conference 2025 November 10, 2025 8:00 AM ESTCompany ParticipantsJames Clemmer - CEO, President &...

AngioDynamics to Participate in the UBS Global Healthcare Conference

2025-10-27
LATHAM, N.Y., October 27, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference at 8:00 a.m. ET on Monday, Nov

H.C. Wainwright Reaffirms Buy Rating on AngioDynamics (ANGO) After Strong Q1 Performance

2025-10-26
AngioDynamics, Inc. (NASDAQ:ANGO) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential. On October 6, H.C. Wainwright reiterated its Buy rating on AngioDynamics (NASDAQ:ANGO) with a price target of $16, following robust fiscal Q1 2026 results. The company posted $75.7 million in net sales, up 12.2% year-over-year, driven by a 26.1% […]

Insider Spends US$112k Buying More Shares In AngioDynamics

2025-10-18
Potential AngioDynamics, Inc. ( NASDAQ:ANGO ) shareholders may wish to note that the CEO, President & Director, James...

AngioDynamics’ NanoKnife® System Named to TIME’s 2025 Best Inventions List

2025-10-13
LATHAM, N.Y., October 13, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its NanoKnife System has been selected as one of TIME's 2025 Best Inventions. The annual list celebrates groundbreaking products and technologies that are transforming how people live, work, and receive care.

AngioDynamics Eyes Growth Despite Tariffs

2025-10-03
AngioDynamics, Inc. (NASDAQ:ANGO) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance. Canaccord Genuity analysts, led by John Young, reiterated their Buy rating on AngioDynamics and increased their price forecast to $18 from $17, citing growth across its portfolio and expectations for positive cash flow in fiscal 2026. First-quarter revenue rose 12.1% to $75.7 million, above consensus, led by a 26.2% jump in Med-Tech sales. Gros

AngioDynamics (ANGO): Losses Worsen, but Forecasted 62% Earnings Growth Challenges Bearish Narratives

2025-10-03
AngioDynamics (ANGO) continues to report negative net profit margin, with losses accelerating at an average rate of 1.3% per year over the last five years and no margin improvement reported in the last twelve months. While revenue is forecast to grow at 6.3% per year, which is below the 9.8% growth projected for the broader US market, earnings are expected to rebound sharply, with a projected growth rate of 62.02% annually and profitability anticipated within the next three years. For...

ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves

2025-10-03
AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains; it also raises FY26 sales outlook, sending shares higher.

We're Hopeful That AngioDynamics (NASDAQ:ANGO) Will Use Its Cash Wisely

2025-10-03
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

AngioDynamics Inc (ANGO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Raised ...

2025-10-02
AngioDynamics Inc (ANGO) reports a 12% revenue increase, driven by Med Tech growth, while navigating tariff impacts and cash reserve declines.